While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily toward branded drugmakers, generic medicines and the companies that manufacture them will be uniquely vulnerable in the event of a trade war given just how “little resilience” the industry enjoys compared to its patented counterpart.
That’s the take according to Ronald Piervincenzi, Ph.D., CEO of the United States Pharmacopeia (USP)—a nonprofit that publishes drug quality, purity, strength and identity standards that are enforced by the FDA and followed by manufacturers....[FiercePharma]
